RWF_10PLK13_Proclaim Registry

Proleukin® Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.

Key Eligibility:

• Must have received at least one course of high dose IL-2 or Proleukin
N/A
NCT01415167
Oncology
Multiple Tumor Types
Brendan Curti, M.D.
Prometheus Laboratories, Inc
Chris Fountain
  • Oncology and Hematology Care Eastside
  • Providence Portland Medical Center